Clinical trials: Metastasis Colorectal Cancer
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer
Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients
This is a multicentre, open-label, Phase I/II study of enadenotucirev in patients with either solid tumour of epithelial origin not responding to standard therapy or for whom no standard treatment exists (Phase I dose escalation…
- Conditions
- Solid Tumours of Epithelial Origin, Metastatic Colorectal Cancer, Metastatic Bladder Cancer
- Trial name
- EVOLVE (NCT02028442)
- Testing
- Enadenotucirev
- Where
- 6 sites in Belgium, Spain
- Volunteers
- 61 people
- Sponsor
- Akamis Bio
Colorectal Neoplasms, Neoplasm Metastasis
Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer
In this study, the investigators assessed whether intraoperative Intraportal infusion of 5-FU and oxaliplatin is able to prevent liver metastasis in patients receiving curative colorectal cancer resection.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms
- Trial name
- NCT01972503
- Testing
- 5-FU and oxaliplatin, colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xu jianmin
Peritoneal Metastases, Peritoneal Carcinomatosis
Changes in Coagulation in Colorectal Cancer Patients Undergoing Surgical Treatment
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has prolonged the survival substantially for selected patients with peritoneal metastases from colorectal cancer.Bleeding and thromboembolic disease…
- Conditions
- Peritoneal Metastases, Peritoneal Carcinomatosis, Colorectal Neoplasms Malignant, Intestinal Neoplasms
- Trial name
- CONTEST (NCT04744688)
- Where
- 2 sites in Denmark
- Volunteers
- 90 people
- Sponsor
- University of Aarhus
Colorectal Cancer Metastatic
Probiotics as Adjuvant Therapy in the Treatment of Metastatic Colorectal Cancer
The research will be prospective, randomised, placebo controlled and double-blinded.The research will be carried on with regards to Helsinki Declaration and following the guidelines of Good Clinical Practice.
- Trial name
- Probat-tmcc-17 (NCT03705442)
- Testing
- Omni-Biotic 10, loperamide ("Seldiar")
- Where
- Croatia
- Volunteers
- 76 people
- Sponsor
- Marin Golčić
Colorectal Cancer, Hematologic Malignancy
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
One of the ways that cancer grows and spreads is by avoiding the immune system.NK cells are immune cells that kill cancer cells, but are often malfunctioning in people with colorectal cancer and blood cancers.
- Conditions
- Colorectal Cancer, Hematologic Malignancy, Rectum Cancer, Acute Myeloid Leukemia
- Trial name
- NCT05400122
- Testing
- Vactosertib, Fludarabine Phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- David Wald
Advanced Cancer, Metastatic Melanoma
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
- Conditions
- Advanced Cancer, Metastatic Melanoma, Metastatic Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT02857270
- Testing
- LY3214996, Midazolam, Abemaciclib
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.
- Trial name
- NCT03542877
- Testing
- Oral Tablet: Cabozantinib
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Metastatic Colorectal Cancer
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Background: Colorectal cancer (CRC) is a major public health problem in the U.S. and worldwide, and 5-year survival with widespread metastatic disease is less than 5%.
- Trial name
- NCT00326495
- Testing
- Cetuximab, BAY 43-9006
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Liver Metastases, Colorectal Cancer
Comparison of Triphasic CT, PET and MR Tumour With Pathological Findings in Colorectal Cancer Liver Metastases
The purpose of this study is to correlate the MRI CT and PET appearances of colorectal liver metastases to pathologic appearance ot better understand the accuracy of imaging to determine tumor size.
- Trial name
- NCT00242086
- Testing
- CT, PET and MRI
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- University Health Network, Toronto
Colo-rectal Cancer
Liver Transplantation and Metastatic Colo-rectal Cancer.
Survival of colo-rectal cancer patients after liver transplantation.
- Trial name
- NCT00294827
- Testing
- Liver transplantation and colo-rectal cancer
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer, Colorectal Adenocarcinoma
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
Doctors leading this study hope to learn about the safety of combining the study drug VS-6766 with another drug called cetuximab in colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma
- Trial name
- NCT05200442
- Testing
- VS-6766/avutometinib, Cetuximab, Pill Diary
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Chicago
Metastatic Colorectal Cancer
A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer
Triplets of irinotecan, oxaliplatin and infusional 5-fluorouracil(FU)/leucovorin (LV) are associated with high response rates and long survival as first-line treatment for metastatic colorectal cancer (mCRC).
- Trial name
- IXO+A (NCT00819754)
- Testing
- IXO regimen + bevacizumab
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Ottawa Hospital Research Institute
Colorectal Cancer, Metastatic to the Liver
Utility of Intra-operative Image Guidance System for Missing Metastases
Intraoperatively, the surgeon will interrogate the liver with ultrasound. The time spent by the surgeon using the ultrasound is recorded.
- Trial name
- NCT02806037
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line…
- Trial name
- NCT00069095
- Testing
- Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg
- Where
- 236 sites in United States, Australia and 31 more
- Volunteers
- 2,035 people
- Sponsor
- Hoffmann-La Roche
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Colorectal Neoplasms
Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer
The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable).
- Trial name
- INVICTAN®-3 (NCT02776683)
- Testing
- BI 695502, Avastin
- Where
- 46 sites in United States, Japan and 2 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer
Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI…
- Trial name
- NCT04799431
- Testing
- Neoantigen Vaccine with Poly-ICLC adjuvant, Retifanlimab
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.